YiChang HEC ChangJiang Pharmaceutical Beheer
Beheer criteriumcontroles 3/4
De CEO YiChang HEC ChangJiang Pharmaceutical is Juncai Jiang, benoemd in May2015, heeft een ambtstermijn van 9.5 jaar. De totale jaarlijkse vergoeding van { bedraagt CN¥ 2.57M, bestaande uit 18.7% salaris en 81.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.008% van de aandelen van het bedrijf, ter waarde HK$ 623.81K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.3 jaar en 7.3 jaar.
Belangrijke informatie
Juncai Jiang
Algemeen directeur
CN¥2.6m
Totale compensatie
| Percentage CEO-salaris | 18.7% |
| Dienstverband CEO | 9.5yrs |
| Eigendom CEO | 0.008% |
| Management gemiddelde ambtstermijn | 7.3yrs |
| Gemiddelde ambtstermijn bestuur | 7.3yrs |
Recente managementupdates
Recent updates
YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Strong Profits May Be Masking Some Underlying Issues
Oct 07
Should You Be Adding YiChang HEC ChangJiang Pharmaceutical (HKG:1558) To Your Watchlist Today?
Sep 19YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Popularity With Investors Under Threat As Stock Sinks 26%
May 29Do YiChang HEC ChangJiang Pharmaceutical's (HKG:1558) Earnings Warrant Your Attention?
Apr 23YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) P/S Is Still On The Mark Following 33% Share Price Bounce
Mar 01Investors Appear Satisfied With YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Prospects As Shares Rocket 33%
Mar 01YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Business Is Trailing The Industry But Its Shares Aren't
Jan 03YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Could Easily Take On More Debt
Sep 25Does YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Have A Healthy Balance Sheet?
Nov 25Is YiChang HEC ChangJiang Pharmaceutical (HKG:1558) A Risky Investment?
Mar 23Does This Valuation Of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Imply Investors Are Overpaying?
Oct 29Here's Why YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Has A Meaningful Debt Burden
Apr 13YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Analysts Just Cut Their EPS Forecasts Substantially
Mar 23YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Share Price Is Down 55% Over The Past Three Years.
Mar 13YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Is Growing Earnings But Are They A Good Guide?
Feb 20
Do Institutions Own YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Shares?
Feb 02YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Dec 26Key Things To Watch Out For If You Are After YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) 5.1% Dividend
Dec 13What Type Of Returns Would YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Nov 30Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥2b |
| Mar 31 2024 | n/a | n/a | CN¥2b |
| Dec 31 2023 | CN¥3m | CN¥482k | CN¥2b |
| Sep 30 2023 | n/a | n/a | CN¥2b |
| Jun 30 2023 | n/a | n/a | CN¥1b |
| Mar 31 2023 | n/a | n/a | CN¥608m |
| Dec 31 2022 | CN¥1m | CN¥600k | CN¥77m |
| Sep 30 2022 | n/a | n/a | -CN¥18m |
| Jun 30 2022 | n/a | n/a | -CN¥113m |
| Mar 31 2022 | n/a | n/a | -CN¥351m |
| Dec 31 2021 | CN¥1m | CN¥490k | -CN¥588m |
| Sep 30 2021 | n/a | n/a | -CN¥436m |
| Jun 30 2021 | n/a | n/a | -CN¥285m |
| Mar 31 2021 | n/a | n/a | CN¥277m |
| Dec 31 2020 | CN¥756k | CN¥229k | CN¥839m |
| Sep 30 2020 | n/a | n/a | CN¥1b |
| Jun 30 2020 | n/a | n/a | CN¥2b |
| Mar 31 2020 | n/a | n/a | CN¥2b |
| Dec 31 2019 | CN¥393k | CN¥222k | CN¥2b |
| Sep 30 2019 | n/a | n/a | CN¥2b |
| Jun 30 2019 | n/a | n/a | CN¥1b |
| Mar 31 2019 | n/a | n/a | CN¥1b |
| Dec 31 2018 | CN¥365k | CN¥209k | CN¥943m |
| Sep 30 2018 | n/a | n/a | CN¥961m |
| Jun 30 2018 | n/a | n/a | CN¥980m |
| Mar 31 2018 | n/a | n/a | CN¥813m |
| Dec 31 2017 | CN¥324k | CN¥194k | CN¥647m |
Compensatie versus markt: De totale vergoeding ($USD 354.98K ) Juncai } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 481.54K ).
Compensatie versus inkomsten: De vergoeding van Juncai is het afgelopen jaar met meer dan 20% gestegen.
CEO
Juncai Jiang (42 yo)
9.5yrs
Tenure
CN¥2,572,000
Compensatie
Mr. Juncai Jiang has been General Manager and Executive Director of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. since joining in May 2015. Mr. Jiang served as Deputy Head of the traditional Chinese med...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| GM & Executive Director | 9.5yrs | CN¥2.57m | 0.0076% HK$ 623.8k | |
| Head of the Sales Department | 10.5yrs | CN¥645.00k | geen gegevens | |
| Deputy GM & Executive Director | 9.5yrs | CN¥2.71m | 0.0076% HK$ 627.9k | |
| Deputy GM & Executive Director | 9.5yrs | CN¥1.32m | 0.0076% HK$ 623.8k | |
| Executive Director | 1.2yrs | CN¥1.59m | geen gegevens | |
| CFO & Head of Finance Department | 5.8yrs | CN¥480.38k | geen gegevens | |
| Chief of Quality Division & Employee Representative Supervisor | 7.3yrs | geen gegevens | 0.0036% HK$ 299.2k | |
| Joint Company Secretary | 6.1yrs | CN¥370.31k | geen gegevens | |
| Joint Company Secretary | 2.8yrs | geen gegevens | geen gegevens |
7.3yrs
Gemiddelde duur
43yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van 1558 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.3 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| GM & Executive Director | 9.5yrs | CN¥2.57m | 0.0076% HK$ 623.8k | |
| Deputy GM & Executive Director | 18.8yrs | CN¥2.71m | 0.0076% HK$ 627.9k | |
| Deputy GM & Executive Director | 6.4yrs | CN¥1.32m | 0.0076% HK$ 623.8k | |
| Executive Director | 1.2yrs | CN¥1.59m | geen gegevens | |
| Chief of Quality Division & Employee Representative Supervisor | 7.3yrs | geen gegevens | 0.0036% HK$ 299.2k | |
| Non-Executive Chairman | 9.5yrs | CN¥32.19m | 0.015% HK$ 1.2m | |
| Independent Non-Executive Director | 9.5yrs | CN¥100.00k | geen gegevens | |
| Supervisor | 7.4yrs | geen gegevens | 0.0076% HK$ 623.8k | |
| Chairman of the Board of Supervisors | 5.4yrs | geen gegevens | geen gegevens | |
| Independent Non Executive Director | 4.4yrs | CN¥100.00k | geen gegevens | |
| Independent Non-Executive Director | 4.2yrs | CN¥340.00k | 0.00045% HK$ 37.0k |
7.3yrs
Gemiddelde duur
46yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van 1558 wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.3 jaar).